Amphastar Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $719.9 | $732.0 | $644.4 | $499.0 | $437.8 |
| Operating income | $140.4 | $205.4 | $197.0 | $107.5 | $69.9 |
| Net income | $98.1 | $159.5 | $137.5 | $91.4 | $62.1 |
| Cash Flow Statement | |||||
| Free cash flow | $121.2 | $172.3 | $145.3 | $65.1 | $70.5 |
| Share repurchases | $75.6 | $85.5 | $58.1 | $39.9 | $28.9 |
Shares outstanding 42.5M · Free float 74.9%
Annual filing data through FY ended December 31, 2025; float as of September 27, 2026.